about
Rho GTPases and their roles in cancer metabolismDeleted in liver cancer-1 (DLC1): an emerging metastasis suppressor geneRas superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cellsmDia1 targets v-Src to the cell periphery and facilitates cell transformation, tumorigenesis, and invasionA phosphorylation switch controls the spatiotemporal activation of Rho GTPases in directional cell migrationDLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activityEpidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2ADLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanismDysregulated serum response factor triggers formation of hepatocellular carcinomaDLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domainDLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathwayRole of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review)Fluctuation of ROS regulates proliferation and mediates inhibition of migration by reducing the interaction between DLC1 and CAV-1 in breast cancer cells.In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-IA novel approach to tag and identify geranylgeranylated proteins.Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer.Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.A feed-forward loop coupling extracellular BMP transport and morphogenesis in Drosophila wingIn vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cellsTargeting mitochondrial glutaminase activity inhibits oncogenic transformation.Detection and Clinical Significance of DLC1 Gene Methylation in Serum DNA from Colorectal Cancer Patients.Genetic differences between Asian and Caucasian chronic lymphocytic leukemia.Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence.Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis.Transglutaminase 2 regulates the GTPase-activating activity of Bcr.NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction.Glutaminase: a hot spot for regulation of cancer cell metabolism?Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.GAP-independent functions of DLC1 in metastasis.Redox regulation of cancer metastasis: molecular signaling and therapeutic opportunities.The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer.Inhibition of cell migration and invasion mediated by the TAT-RasGAP317-326 peptide requires the DLC1 tumor suppressor.RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7).DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1.Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma.Deleted in liver cancer 1 expression and localization in hepatocellular carcinoma tissue sections.Resveratrol inhibits proliferation and migration through SIRT1 mediated post‑translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells.PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis.
P2860
Q27003967-3F6B1363-AF0B-49ED-8ED1-2AF0EC44F0A2Q27025409-173BF0E1-4DD9-414A-BA7B-3EF9284FF95EQ27690752-B7033CAC-282C-484B-947A-5E396504AF22Q28383203-70459E67-8EB6-44C8-9B93-F7E11C70918FQ28383800-87BF6EEB-5C9F-4947-A94A-D11739BE549BQ28384095-CCB4B85E-9498-42FB-B2C9-2972E9FCA481Q28385400-F02EFA97-9B42-4BF1-844E-13A4BF907D02Q28387833-87B2B617-22E4-449A-90B6-AFFA96820B1EQ28387959-D6954F44-400E-4E32-AC38-B50C08F08CFAQ28390147-BA94801C-A07F-436D-AAAA-53316C806AF2Q28391564-AC5B0F06-7CD1-4462-94DF-0A43CC4C1A44Q28392462-C74AF9F6-75AA-4FE7-921B-88DF16DB9F1BQ28394917-41D126BA-4655-44D7-B757-ECF73C338D75Q32182663-CA63AE34-C693-489E-BD70-5FA376E9F40EQ33439394-44BC0B8F-6152-4BB1-9154-276ED2B05E77Q33791208-536D6FEA-6539-4171-9202-5E02A91C0995Q34278253-01514444-F9AA-4FFA-9ABA-F8AB2889EA4AQ34285684-6002ED69-76A1-45F5-AE6C-F3227E06250BQ34649987-AF28AFBF-460B-4482-8451-69CFB70FED4DQ34680671-7DFB82E0-074E-4E73-86B1-90D757D19F81Q34807996-65ED2766-9C1C-4AC7-90FF-BC1AF2FD04C6Q36551119-66A121A4-A849-426D-A142-74F017BCD501Q37178396-59C4AE41-ED79-44BF-A3E1-E96958F0B754Q37236908-DBBFA972-A8BA-486E-9509-788A4ECDCE8FQ37374847-5DFF3BB9-ECD3-465D-A0B2-C8F9E380FD7DQ37467642-7E5AFE8C-4063-4BC9-851F-C27CB70542D6Q37687440-7A2E5526-45D8-484D-AA37-9159234E4754Q37828397-ACB85E71-163F-4551-A7EB-7C82DBCCE274Q38151489-7165065D-7E42-48BF-8D40-A9D4661269D5Q38171331-3FC5BB73-394F-4E8F-811B-28E352050F14Q38243631-CBC6ADDF-99EB-44E6-ABD7-F4BB2610B9B9Q38991996-938D76C9-A471-48A8-A486-51E9A86208A4Q39064888-0D3480D5-D4BD-47FE-9E3F-C9DFCA73723FQ39085721-9AEC4A25-00B0-4975-A21E-783ED0F4BAB9Q39200334-606A77F7-B017-4C51-92DC-FE2E71535C0AQ39433431-9C4C56FD-60AE-443F-9EFB-EC24EB9A3AE2Q39696941-ADE73CAF-95E2-4879-BF8F-14E5919A06F8Q41836476-184B5577-59FD-4C4E-94DF-AF9BD9F68968Q47688950-D12CF675-F932-437F-8088-A937C59E1393Q53256531-88149D7B-0A67-42C4-A2F1-2B8B75998AB9
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
DLC1: a significant GAP in the cancer genome
@ast
DLC1: a significant GAP in the cancer genome
@en
DLC1: a significant GAP in the cancer genome
@nl
type
label
DLC1: a significant GAP in the cancer genome
@ast
DLC1: a significant GAP in the cancer genome
@en
DLC1: a significant GAP in the cancer genome
@nl
prefLabel
DLC1: a significant GAP in the cancer genome
@ast
DLC1: a significant GAP in the cancer genome
@en
DLC1: a significant GAP in the cancer genome
@nl
P2860
P356
P1433
P1476
DLC1: a significant GAP in the cancer genome
@en
P2093
Aurelia Lahoz
P2860
P304
P356
10.1101/GAD.1691408
P407
P577
2008-07-01T00:00:00Z